Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5263]

Darovasertib plus crizotinib improves outcomes in HLA-A2–negative metastatic...

Dr Marlana Orloff - Thomas Jefferson University Hospital, Philadelphia, USA

Darovasertib plus crizotinib improves outcomes in HLA-A2–negative metastatic uveal melanoma ( Dr Marlana Orloff - Thomas Jefferson University Hospital, Philadelphia, USA )

Early-onset gastrointestinal cancers show more advanced disease and wider...

Dr Jessica Paulus - Ontada, Boston, USA

Early-onset gastrointestinal cancers show more advanced disease and wider racial survival gaps ( Dr Jessica Paulus - Ontada, Boston, USA )

Xaluritamig plus abiraterone shows promising anti-tumour activity with...

Dr David Pook - Monash Health, Melbourne, Australia

Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC ( Dr David Pook - Monash Health, Melbourne, Australia )

Tarlatamab improves brain metastases control and survival compared to chemo in...

Dr Giannis Mountzios - The University of Athens, Athens, Greece

Tarlatamab improves brain metastases control and survival compared to chemo in SCLC ( Dr Giannis Mountzios - The University of Athens, Athens, Greece )

miR371 shows promise as a surveillance biomarker for relapse in early-stage...

Dr Lucia Nappi - University of British Columbia, Vancouver, Canada

miR371 shows promise as a surveillance biomarker for relapse in early-stage germ cell tumours ( Dr Lucia Nappi - University of British Columbia, Vancouver, Canada )

Implanted tile-based radiation shows promise compared with stereotactic...

Dr Jeffrey Weinberg - MD Anderson Cancer Center, Houston, USA

Implanted tile-based radiation shows promise compared with stereotactic radiotherapy for brain metastases ( Dr Jeffrey Weinberg - MD Anderson Cancer Center, Houston, USA )

Lorlatinib delivers 7-year progression-free survival and durable brain control...

Prof Tony Mok - Chinese University of Hong Kong, Ma Liu Shui, Hong Kong

Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC ( Prof Tony Mok - Chinese University of Hong Kong, Ma Liu Shui, Hong Kong )

ASCO 2026: Latest updates in mRCC

Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke

ASCO 2026: Latest updates in mRCC ( Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke )

Adagloxad simolenin plus OBI-821 shows no survival benefit compared to standard...

Dr Hope Rugo - City of Hope, Duarte, USA

Adagloxad simolenin plus OBI-821 shows no survival benefit compared to standard of care in triple-negative breast cancer ( Dr Hope Rugo - City of Hope, Duarte, USA )

ASCO 2026: Breast cancer overview

Dr Hope Rugo - City of Hope, Duarte, USA

ASCO 2026: Breast cancer overview ( Dr Hope Rugo - City of Hope, Duarte, USA )

mRNA-4359 plus pembrolizumab shows high response rates and robust T-cell...

Dr Pavlina Spiliopoulou - Beatson West of Scotland Cancer Centre, Glasgow, UK

mRNA-4359 plus pembrolizumab shows high response rates and robust T-cell activation in melanoma ( Dr Pavlina Spiliopoulou - Beatson West of Scotland Cancer Centre, Glasgow, UK )

Combination therapeutic strategies for aRCC patients with bone metastases

Prof Stéphane Oudard and Dr Stefanie Zschäbitz

Combination therapeutic strategies for aRCC patients with bone metastases ( Prof Stéphane Oudard and Dr Stefanie Zschäbitz )

More from ecancer